Aurobindo Pharma Limited has informed the Exchange about General Updates
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The US FDA inspected Unit-IV of APL Healthcare Limited, a wholly owned subsidiary of Aurobindo Pharma, located in Naidupeta Mandal, SPSR Nellore District, Andhra Pradesh, from December 8 to December 17, 2025. At the end of the inspection, the FDA issued a Form 483 with 5 observations. The unit has now received an Establishment Inspection Report (EIR) classifying the facility as 'Voluntary Action Indicated' (VAI), and the inspection has been officially closed. A VAI classification means the FDA did not find significant regulatory violations requiring mandatory action, though the observations should be voluntarily addressed.
This is a positive development for Aurobindo Pharma as VAI is a favorable outcome that removes near-term regulatory overhang on this facility, though the 5 observations remain to be voluntarily addressed. The closure allows the unit to continue supplying the US market without restrictions.